August 31, 2026

Samsung PolyPeptide Tender Prospectus, Ascendis-BioMarin YUVIWEL Settlement, BioVie ADDRESS-LC Complete, Lexicon SOLOIST-WHF

Samsung publishes PolyPeptide tender prospectus, Ascendis-BioMarin settle YUVIWEL patent dispute with royalties, BioVie completes Long COVID Phase 2.

10 stories · Covering industry, clinical-trials, research, regulatory

Editor's Note

Monday closed August with two peptide-industry M&A milestones landing on the same day and the last major ESC Congress publications rolling out from Munich. Samsung Biologics's Swiss subsidiary Samsung Peptide AG published the formal tender offer prospectus for PolyPeptide Group AG (CHF 44.31 per share, CHF 1.46 billion equity value, offer period September 15 to October 12), triggering the cooling-off period that runs from September 1 and confirming the largest peptide CDMO consolidation of the year. On the same morning, Ascendis Pharma and BioMarin announced a binding term sheet resolving the international YUVIWEL (navepegritide, TransCon C-type natriuretic peptide for achondroplasia) patent litigation: Ascendis gets a worldwide non-exclusive license and BioMarin gets 20% U.S. and 18% EU/Brazil/Korea royalties through May 20, 2030, plus dismissal of the ITC Section 337 investigation and litigation in five countries. Clinical: BioVie completed Bezisterim ADDRESS-LC Phase 2 treatment for Long COVID neurological symptoms with topline expected end of September, Lexicon's SOLOIST-WHF post-hoc showing sotagliflozin benefit across blood-pressure ranges was presented at ESC and published in JACC: Heart Failure, and Enveda's exercise-mimetic ENV-308 Phase 1 read out earlier in the month with lean-mass-preservation signals relevant to the post-GLP-1 discontinuation problem. Global Peptide Synthesis Market Outlook projected the category at $7 billion by 2035 (5.2% CAGR from $4.4 billion in 2026).

Industry

Samsung Peptide AG Publishes Formal Tender Offer Prospectus for PolyPeptide Group AG; Offer Period September 15 to October 12, 2026

Samsung Biologics (KRX: 207940), through its Swiss subsidiary Samsung Peptide AG, published Monday August 31, 2026 the formal tender offer prospectus for all publicly held registered shares of PolyPeptide Group AG (SIX: PPGN) on SIX Swiss Exchange. Terms: CHF 44.31 net in cash per share (implied equity value approximately CHF 1.46 billion / $1.8 billion, a 40% premium to the CHF 31.65 undisturbed share price of April 10, 2026). The cooling-off period runs 10 SIX trading days from September 1, and the main offer period commences September 15, 2026 through October 12, 2026 at 4 p.m. Swiss time. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares) has committed to tender all shares. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals; transaction close is targeted for end of 2026. Samsung intends to squeeze out remaining minorities and delist PolyPeptide post-close, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into the Incheon multi-modality biologics footprint.

#samsung-biologics #samsung-peptide-ag #polypeptide-group #tender-offer-prospectus #chf-44-31-per-share #1-46-billion-chf #offer-period-september-15 #cooling-off-period #draupnir-holding #66-2-3-percent-threshold #peptide-cdmo-consolidation

Industry

Ascendis Pharma and BioMarin Enter Binding Global Settlement and License Term Sheet for YUVIWEL (Navepegritide); 20% U.S. and 18% EU/Korea/Brazil Royalties Through May 2030

Ascendis Pharma (NASDAQ: ASND) and BioMarin Pharmaceutical (NASDAQ: BMRN) announced Monday August 31, 2026 a binding term sheet for a global settlement and license agreement resolving all litigation and disputes related to YUVIWEL (navepegritide, TransCon C-type natriuretic peptide for achondroplasia and hypochondroplasia). Terms: BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to continue researching, developing, manufacturing, and commercializing navepegritide-related products without restriction, and waives certain regulatory rights and exclusivities. Ascendis makes royalty payments to BioMarin of 20% on U.S. net sales and 18% on European Union, South Korea, and Brazil net sales from first commercial sale through May 20, 2030. BioMarin dismisses the pending U.S. International Trade Commission Section 337 investigation plus litigation in Brazil, Denmark, Germany, South Korea, and the U.S. Northern District of California. The settlement covers all current and potential YUVIWEL indications, including achondroplasia and hypochondroplasia, and removes the largest overhang on the Ascendis TransCon peptide platform.

#ascendis-pharma #asnd #biomarin #bmrn #yuviwel #navepegritide #transcon-cnp #achondroplasia #hypochondroplasia #global-settlement #20-percent-us-royalty #18-percent-eu-korea-brazil-royalty #may-2030-royalty-end #itc-337-dismissed

Clinical Trials

BioVie Completes Bezisterim ADDRESS-LC Phase 2 Long COVID Treatment Phase; Topline Data Expected Before End of September 2026

BioVie Inc. (NASDAQ: BIVI) announced Monday August 31, 2026 completion of the last on-treatment visit in the ADDRESS-LC Phase 2 trial evaluating Bezisterim (a small-molecule insulin-sensitizer developed for the treatment of neurological symptoms of Long COVID). The Phase 2 study enrolled approximately 200 patients to evaluate whether Bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms after SARS-CoV-2 infection, and is fully funded by a grant from the U.S. Department of War (formerly Department of Defense). With the last patient's treatment visit complete and the one-month virtual follow-up nearly complete, BioVie anticipates topline results before end of September 2026. Not a peptide, but the readout is relevant to the peptide-industry Long COVID pipeline (LSALT peptide, BPC-157 for post-viral inflammation) and reflects the broader Department of War / BARDA interest in post-acute infection syndrome treatments.

#biovie #bivi #bezisterim #address-lc #long-covid #phase-2 #neurological-symptoms #brain-fog #department-of-war #dod-funded #topline-september-2026 #non-peptide

Research

Lexicon Sotagliflozin SOLOIST-WHF Post-Hoc Analysis Shows Consistent Heart Failure Benefit Across Baseline Systolic Blood Pressure at ESC 2026 and JACC: Heart Failure

Lexicon Pharmaceuticals (NASDAQ: LXRX) presented Monday August 31, 2026 at ESC Congress 2026 Munich a post-hoc analysis of the Phase 3 SOLOIST-WHF trial of sotagliflozin (INPEFA, a dual SGLT1/SGLT2 inhibitor) evaluating efficacy and safety across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The analysis was simultaneously published in JACC: Heart Failure (DOI 10.1016/j.jchf.2026.103368). Results: sotagliflozin's cardiovascular death and heart-failure-related event reduction was maintained regardless of baseline systolic blood pressure, including in patients with baseline SBP as low as 100 mmHg, without an increase in hypotension or acute kidney injury. The subgroup analysis strengthens the SGLT1/SGLT2 inhibitor commercial case in worsening heart failure where the class has historically been under-utilized due to concerns about hemodynamic tolerability in lower-blood-pressure patients.

#lexicon-pharmaceuticals #lxrx #sotagliflozin #inpefa #sglt1-sglt2-inhibitor #soloist-whf #worsening-heart-failure #systolic-blood-pressure-subgroup #esc-2026 #jacc-heart-failure #post-hoc-analysis #non-peptide

Clinical Trials

Enveda Reports Positive Phase 1 Results for ENV-308 Exercise-Mimetic Pill Targeting Post-GLP-1 Weight Maintenance and Lean Mass Preservation

Enveda Biosciences (Boulder, Colorado, AI-enabled natural product discovery platform) reported positive Phase 1 results August 18, 2026 for ENV-308, a first-of-its-kind oral small molecule engineered to mimic the therapeutic effects of Lac-Phe (a hormone released during intense exercise) for the treatment of post-GLP-1 weight regain and lean-mass loss. In the Phase 1 trial (n=88 healthy volunteers), ENV-308 was extremely well tolerated including on gastrointestinal safety, and reduced circulating leptin as an exploratory metabolic-engagement signal. In animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that 1 in 8 U.S. adults use GLP-1 medications and the majority who take them for weight loss stop within one year. Phase 2 will test whether ENV-308 can help people maintain weight after stopping GLP-1s. Not a peptide, but the exercise-mimetic pathway is one of the leading commercial answers to the muscle-preservation and post-discontinuation regain problems that constrain the current peptide obesity therapeutic class.

#enveda-biosciences #env-308 #lac-phe #exercise-mimetic #post-glp-1-weight-maintenance #lean-muscle-preservation #phase-1 #88-volunteers #leptin-reduction #ai-natural-product-discovery #non-peptide

Industry

Global Peptide Synthesis Market Outlook Report Projects $7 Billion by 2035 at 5.2% CAGR Driven by GLP-1 Demand and CDMO Capacity Expansion

Global Peptide Synthesis Market Outlook Report 2026-2035 was published August 31, 2026 via ResearchAndMarkets, projecting global peptide synthesis market growth from $4.4 billion in 2026 to $7.0 billion by 2035 (5.2% CAGR). Growth drivers: growing peptide therapeutics pipeline, rising demand for peptide active pharmaceutical ingredients, continued investment in manufacturing infrastructure, and increased outsourcing to specialized peptide CDMOs. Named anchor programs: CordenPharma more than EUR 900 million capacity investment; PolyPeptide doubling capacity at its Malmö site (in the context of the pending Samsung Biologics acquisition); Cambrex expanding its Waltham, Massachusetts facility. Regulatory context: authorities worldwide have approved nearly 100 peptide-based therapies across cancer, diabetes, chronic pain, HIV, multiple sclerosis, and osteoporosis. Report caveats: the top-line 5.2% CAGR reflects a broad market definition; a narrower peptide CDMO subsegment (Bachem, PolyPeptide, CordenPharma, AmbioPharm) is growing at 20%+ CAGR per multiple industry data sources given the incretin surge.

#peptide-synthesis-market #7-billion-by-2035 #5-2-percent-cagr #peptide-cdmo #cordenpharma-900-million #polypeptide-malmo #cambrex-waltham #glp-1-demand #100-approved-peptides #market-outlook-report

Research

Cytokinetics ACACIA-HCM Additional Analyses Published in Circulation; MAPLE-HCM in JACC: Heart Failure Following ESC 2026 Late-Breaking Presentation

Cytokinetics (NASDAQ: CYTK) confirmed Monday August 31, 2026 the peer-reviewed publication of ACACIA-HCM additional analyses in Circulation and MAPLE-HCM in Journal of the American College of Cardiology: Heart Failure, both following the ESC Congress 2026 Late-Breaking Clinical Trial Session presentations Saturday August 29 in Munich. The ACACIA-HCM Circulation paper details cardiac structure and diastolic function improvements from aficamten (Myqorzo) in symptomatic non-obstructive hypertrophic cardiomyopathy (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), supporting the ACACIA-HCM primary readout (KCCQ Clinical Summary Score and peak VO2) that was presented Friday August 28 in the Hot Line Session and published simultaneously in the New England Journal of Medicine. The MAPLE-HCM JACC: Heart Failure paper reports the trial of aficamten versus metoprolol in obstructive HCM. Cytokinetics plans an aficamten sNDA submission in Q4 2026 for the non-obstructive HCM indication.

#cytokinetics #cytk #myqorzo #aficamten #acacia-hcm #maple-hcm #circulation #jacc-heart-failure #non-obstructive-hcm #obstructive-hcm #metoprolol-comparator #esc-2026 #snda-q4-2026

Regulatory

Rein Therapeutics LTI-03 UK MHRA Phase II Clearance for RENEW Trial in Idiopathic Pulmonary Fibrosis; Caveolin-1 Peptide Mimetic Class

Rein Therapeutics (NASDAQ: RNTX) received UK Medicines and Healthcare products Regulatory Agency (MHRA) clearance in August 2026 to initiate the Phase 2 RENEW study of LTI-03 (a Caveolin-1 scaffolding domain peptide mimetic developed for the treatment of idiopathic pulmonary fibrosis, or IPF). The RENEW study is planned to enroll 120 patients with IPF and evaluate LTI-03 as an add-on to standard-of-care antifibrotic therapy (pirfenidone or nintedanib). The Caveolin-1 mimetic peptide mechanism engages the fibrotic signaling that emerges downstream of alveolar epithelial cell injury and has been characterized in preclinical fibrosis models. Rein Therapeutics is the successor entity to the 2024 reverse merger between Aileron Therapeutics and Lung Therapeutics, and LTI-03 is the lead clinical asset. The Phase 2 initiation extends the small-but-substantive peptide-therapeutic pipeline in fibrotic disease (Sitryx SIT-402, MediciNova ibudilast) beyond the incretin obesity focus that dominates recent peptide-industry headlines.

#rein-therapeutics #rntx #lti-03 #caveolin-1 #peptide-mimetic #idiopathic-pulmonary-fibrosis #ipf #renew-study #phase-2 #uk-mhra-clearance #pirfenidone #nintedanib #aileron-lung-therapeutics-merger

Clinical Trials

AstraZeneca-Ionis Wainua (Eplontersen) CARDIO-TTRansform Full Data at ESC 2026 Sunday August 30; Monotherapy Subgroup HR 0.71 With No Effect on Baseline Stabilizer Patients

AstraZeneca (NASDAQ: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) presented Sunday August 30, 2026 at ESC Congress 2026 Munich the detailed subgroup analyses from the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen, an antisense oligonucleotide targeting transthyretin) in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). CARDIO-TTRansform did not meet its primary composite endpoint (cardiovascular mortality plus recurrent CV events through 140 weeks) versus placebo. In the prespecified subgroup analysis, patients receiving eplontersen monotherapy achieved a nominally significant hazard ratio of 0.71 versus placebo, while patients on background TTR stabilizer therapy (tafamidis, Vyndaqel/Vyndamax) at baseline showed no treatment effect. The read-out complicates the silencer-plus-stabilizer commercial approach in ATTR-CM that Alnylam's HELIOS-B trial of vutrisiran validated with 28.2% mortality reduction and 32.8% CV event reduction on background tafamidis. AstraZeneca and Ionis will analyze the full dataset to inform next steps in the CARDIO-TTRansform program.

#astrazeneca #azn #ionis-pharmaceuticals #ions #wainua #eplontersen #cardio-ttransform #attr-cm #antisense-oligonucleotide #primary-endpoint-miss #monotherapy-subgroup-hr-0-71 #esc-2026 #vutrisiran-comparator #helios-b-comparator #silencer-plus-stabilizer

Industry

Roche Pharma Day September 28 Preview: Petrelintide, Enicepatide, HM17321 Positioned as Top-Three Global Obesity Portfolio Update Ahead of EASD 2026

Roche (SIX: ROG) is scheduled to hold its Pharma Day investor event Monday September 28, 2026, providing updates across the R&D portfolio including three top-three-position obesity assets: petrelintide (amylin analog partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, ZUPREME-1 documented 10.7% weight loss at 42 weeks, Phase 3 monotherapy initiation planned late 2026); enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2); and HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties; Genentech takes over from Phase 2 forward). The Pharma Day briefing frames Roche as a credible third-place global obesity competitor behind Eli Lilly (Zepbound-Mounjaro-Foundayo plus upcoming retatrutide) and Novo Nordisk (Wegovy-Ozempic plus CagriSema plus amycretin), with EASD 2026 Rome September 28-October 2 the immediate downstream data catalyst.

#roche #rog #pharma-day-september-28 #petrelintide #enicepatide #ct-388 #hm17321 #urocortin-2-crfr2 #genentech-hanmi #zealand-pharma #top-three-obesity #easd-2026-rome #amylin-analog #glp-1-gip